Results
inflammation, ASCVD
INFLAMMATION, ASCVD
Basal anamnestic and anthropometric parameters, as well as clinical, metabolic and inflammation parameters of the two groups of patients, treated with pioglitazone or glimepiride, are illustrated in Clinical and metabolic parameters of the two groups of patients.
**FPG, fasting plasma glucose; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; CPR, C-reactive protein.10-year ASCVD risk was calculated according to After the 5-year treatment period, no significant differences were found between groups, except for a marginal significance of systolic blood pressure (With respect the specific parameters of glyco-oxidation (Comparisons for AGE, s-RAGE and AGE/s-RAGE data in the two groups of patients at both considered times.
Distribution of Δ values for glyco-oxidation parameters in the two groups of patients. The edges of the boxes indicate the 25Merging the data of the two groups (AGE, s-RAGE and AGE/s-RAGE data considering patients altogether at both considered times.
Again, considering all the patients, a possible correlation among differences in the available parameters at the end of the 5-year treatment was evaluated (